Ensysce’s Insider Deal Signals Bold Shift Toward Neuro‑Plastic Pain Therapy with Cy 200
Ensysce’s insider move signals a strategic shift: merger with neuro‑plastic drug Cy 200, orphan‑drug exclusivity, and a potential $/share boost—watch for clinical milestones and dilution impact.
4 minutes to read